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Abstract
Background:  Bacteria that belong to the genus Sphingobacterium  are Gram-negative, non-
fermentative bacilli, ubiquitous in nature and rarely involved in human infections. The aims of this
study were to evaluate the epidemiology of infection by Sphingobacterium in a cohort of patients
affected by Cystic Fibrosis (CF), the antibiotic susceptibility and the DNA fingerprinting of the
isolated strains and to analyze some clinical outcomes of the infected patients.
Findings: Between January 2006 and June 2008, patients (n = 332) attending the Regional CF Unit
in Naples, Italy, were enrolled.
Sputum samples were processed for microscopic, cultural, phenotypic identification and antibiotic
susceptibility testing. DNA fingerprinting was performed by pulsed-field gel electrophoresis
(PFGE). A total of 21 strains of Sphingobacterium were isolated from 7 patients (13 of S. spiritovorum,
8 of S. multivorum). S. multivorum isolates were more resistant than those of S. spiritovorum. PFGE
profiles were in general heterogeneous, which suggested independent circulation.
Conclusions: This is the first Italian report about respiratory tract infections by Sphingobacterium
in CF patients. In our cohort, these infections were not associated with a deterioration of
pulmonary function during the follow-up period. Although the exact role of this microorganism in
CF lung disease is unknown and the number of infected patients was small, this study could
represent an important starting-point for understanding the epidemiology and the possible
pathogenic role of Sphingobacterium in CF patients.
Findings
In Cystic Fibrosis (CF) patients, bronchiectasis and
obstructive pulmonary disease are the primary causes of
morbidity and mortality [1]. As pulmonary disease ther-
apy and nutritional care have improved life expectancy,
new emerging pulmonary pathogens, such as bacteria of
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the Burkholderia cepacia complex, Alcaligenes xylosoxidans,
Stenotrophomonas maltophilia and nontuberculous myco-
bacteria have been detected in CF patients [2-8].
Bacteria that belong to the genus Sphingobacterium  are
Gram-negative, non-fermentative microorganisms that
are positive for catalase and oxidase tests. They are ubiqui-
tous in nature, but are rarely involved in human infec-
tions. An important feature of bacteria that belong to this
genus is the presence of high concentrations of sphingo-
phospholipids in the cellular lipid components, from
which the name Sphingobacterium is derived. The genus
Sphingobacterium consists of six species: S. spiritovorum, S.
multivorum, S. mizutaii, S. antarcticum, S. faecium and S.
thalpophilum. The species S. multivorum and S. spiritovorum
have been associated with bacteremia, peritonitis, and
chronic respiratory infection in patients with severe
underlying conditions [9-13].
In the last years, some strains of Sphingobacterium have
been isolated from respiratory samples of CF patients
attending our Regional CF Center.
The finding of these microorganisms in our CF patients
led us to investigate this phenomenon. Therefore, in this
study, we investigated the prevalence of infection by
Sphingobacterium in a cohort of CF patients and examined
the antibiotic susceptibility of these strains. In addition,
we performed DNA fingerprinting and analyzed some
clinical outcomes of patients infected by these bacteria.
Methods
Study population
Microbiological samples (sputum) were obtained during
the period January 2006 to June 2008 from 332 CF
patients (147 males, 185 females; mean age 18.15 years;
range 0.5-52 years) who were regularly attending the
Regional Referral CF Center of Naples. CF diagnosis was
confirmed by standard methods (sweat chloride concen-
tration above 60 mmol/L) and by genetic analysis.
At each visit, body weight and body mass index, number
of episodes of pulmonary exacerbation, number and
duration of hospital admissions required for pulmonary
exacerbation and number of intravenous administrations
of antibiotics were registered on an electronic case report
form. Patients over 6 years of age had at least one evalua-
tion of lung function per year as measured by forced expir-
atory volume in 1 sec (FEV1), and expressed as a
percentage of predicted values for the relevant age, sex,
ethnic background, weight and height.
Sputum samples for microbiological studies were
obtained from each patient at least quarterly at clinical
examinations.
Chronic lung infection was defined as the persistence of
pathogen in three positive cultures for at least six consec-
utive months [14]. Co-infection was defined as the pres-
ence of more than one microorganism in the sputum
sample.
Patients infected by Sphingobacterium were characterized
for age, age of acquisition of first infection, co-infection
and lung function.
Multidrug resistance was assessed according to the guide-
lines of the CF Foundation for P. aeruginosa [15], which
were extended to all Sphingobacterium isolates.
This study was conducted in agreement with the Declara-
tion of Helsinki.
Processing of samples, culture and identification of 
microorganisms
Sputum samples obtained from all patients during the
study period were mixed with an equal volume of 1%
dithiothreitol before incubation at 37°C for 30 min. All
specimens were examined microscopically and plated on
several agar media, which included blood agar, Muller-
Hinton agar, MacConkey agar, Burkholderia cepacia selec-
tive agar (BCSA) and Sabouraud agar, at 37°C for up to 72
h.
All isolates obtained from the samples were identified
using the Phoenix system (Becton Dickinson) and, for the
identification of Gram-negative non-fermentative bacte-
ria, the API 20 NE identification system (bioMérieux) was
also used.
Isolates that were identified as S. multivorum or S. spiritovo-
rum  were processed for DNase, oxidase, urease activity
and motility tests [16].
The DNase activity was tested using the method of
O'Brien and Davis [17]: briefly, DNase test agar (DNase
agar CM321, Oxoid) that contained 0.01% (vol/vol) tolu-
idine blue was used. The plates were examined for pink
zones around the colonies. In the absence of dye, the
plates were flooded with 1 N HCl, allowed to stand on the
bench (lids uppermost) for a few minutes and then exam-
ined for clear zones around the colonies. For the oxidase
test, Taxo Discs (BBL™) were used. For the urease test, Urea
Agar Slants (BBL™) were used. For the motility test, colo-
nies were inoculated into Motility GI Medium tubes
(Difco) and incubated at 37°C for 18 h. Motility was indi-
cated by diffuse bacterial growth away from the inoculum
zone.
Antibiotic-susceptibility test
To assess the sensitivity of the Sphingobacterium isolates to
antibiotics, an agar-diffusion method (Kirby-Bauer) and aBMC Research Notes 2009, 2:262 http://www.biomedcentral.com/1756-0500/2/262
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microbroth dilution assay (Phoenix) were used. For all
the methods used in the study, interpretative criteria for
susceptibility to antibiotics were in accordance with
National Committee for Clinical Laboratory Standards
criteria [18]. The following drugs were assayed: amikacin,
aztreonam, piperacillin, piperacillin-tazobactam, cefotax-
ime, cefepime, ceftazidime, ciprofloxacin, levofloxacin,
chloramphenicol, imipenem, meropenem, trimethoprim-
sulfamethoxazole and gentamicin.
Genotyping by PFGE
DNA fingerprinting was carried out by the method
described by Grothues et al. [19]. Briefly, isolates were
grown overnight and suspended in SE buffer (75 mM
NaCl, 25 mM EDTA, pH 7.5). The cell suspensions (4
McFarland units) were mixed with an equal volume of
1.6% low-melting point agarose, molded into plugs at
4°C, and lysed with lysis buffer (1% N-lauryl sarcosine,
0.5 M EDTA, pH 8) to which Proteinase K (500 μg/mL)
had been added. The DNA inserts were digested by ApaI
(New England Biolabs), in accordance with the manufac-
turer's instructions. Macrorestriction fragments were sepa-
rated using the CHEF-DR III PFGE system (Bio-Rad) at
10°C for 20 h, with an initial switch time of 5 s and a final
switch time of 35 s, at a field strength of 6 V/cm. A ladder
of lambda phage DNA concatemers was used as a size
marker. Fragment patterns were compared according to
the criteria described by Tenover [20]. Based on these cri-
teria, we considered isolates to be possibly related if their
restriction patterns differed by 4-6 bands and closely
related if their restriction patterns differed by no more
than 2-3 bands. Isolates were considered different if their
restriction patterns differed by 7 or more bands.
Results
Infected and chronically-infected patients, co-infection 
with other microorganisms
During the study period, a total of 21 isolates of Sphingo-
bacterium was detected (8 isolates of S. multivorum and 13
isolates of S. spiritovorum) from 7 of the 332 patients
enrolled (2.1%; 2 males, 5 females). S. spiritovorum was
isolated from four patients and S. multivorum was isolated
from three patients. Among these, one patient was identi-
fied as chronically infected by S. multivorum.
All patients were co-infected by at least one other Gram-
negative pathogen, and in four patients, co-infection by
Gram-positive bacteria was also found (as indicated in
table 1).
Identification of S. multivorum and S. spiritovorum
These bacteria showed growth on blood agar, on which
they appeared as convex, smooth, opaque, non-hemolytic
colonies of 1 mm in diameter after 48 h of incubation at
37°C. Although they appeared as small yellow colonies
on Mueller-Hinton medium after 24 h of incubation at
37°C, no growth or limited growth was observed on Mac-
Conkey agar. The bacteria did show growth on BCSA after
48 h of incubation at 37°C.
All 21 isolates of Sphingobacterium were non-motile and
positive for DNAse, oxidase and urease tests.
The automated system used for identification had a relia-
bility level of 99% for the above mentioned bacteria and
identification was confirmed by the API 20 NE system.
Antibiotic-susceptibility test
On the basis of the criteria applied in this study, all the S.
multivorum isolates showed multidrug resistance, whereas
the S. spiritovorum isolates were not considered multire-
sistant. In particular, the S. multivorum isolates were resist-
ant to β-lactams, including carbapenems and
aminoglycosides; only trimethoprim-sulfamethoxazole
(minimum inhibitory concentration-MIC<0.5/9.5 μg/
mL) and quinolones (ciprofloxacin, MIC<0.5 μg/mL; lev-
ofloxacin, MIC<1 μg/mL) were active against these strains.
The S. spiritovorum isolates showed sensitivity to ceftazi-
dime, carbapenems, trimethoprim-sulfamethoxazole and
quinolones (as indicated in table 2).
Genome macrorestriction analysis
PFGE analysis showed a high heterogeneity of restriction
patterns. All 7 patients were infected by strains that were
Table 1: Co-infection with other bacteria, type of CFTR mutation and pancreatic insufficiency in patients with Sphingobacterium 
infection
Strains Number of patients Co-infection with other bacteria CFTR mutation Number of patients with PI
S. spiritovorum 4 (3 Females/1 Male) P. aeruginosa (1 patient),
P. aeruginosa+S. maltophilia+S. aureus (1 
patient),
P. aeruginosa+S. aureus (2 patients)
ΔF508 (2 patients),
ΔF508/Ot (1 patient),
Ot/Ot (1 patient)
4
S. multivorum 3 (2 Females/1 Male) P. aeruginosa+S. marcescens (1 patient),
S. marcescens (1 patient),
P. aeruginosa+S. aureus (1 patient)
ΔF508 (1 patient),
ΔF508/Ot (1 patient),
Ot/Ot (1 patient)
3
Ot: Other;
PI: pancreatic insufficiencyBMC Research Notes 2009, 2:262 http://www.biomedcentral.com/1756-0500/2/262
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epidemiologically different (strains A-G) (Fig. 1). Moreo-
ver, sequential isolates taken from same patient had iden-
tical PGFE profiles.
Clinical manifestations
Of the 7 patients infected by Sphingobacterium (mean age
10.8 years, range 4-24 years) all showed pancreatic insuf-
ficiency at CF diagnosis. The mean age at diagnosis was
13.4 months (range 5 months-22 years), whereas the
mean age at first acquisition of Sphingobacterium infection
was 6.5 years (range 1-15.5 years). The results of the
genetic analysis showed that three of the patients were
homozygous for the ΔF508 mutation, two were hetero-
zygous for ΔF508 and another mutation and two were
heterozygous for other mutations (see table 1).
During the follow-up period (mean period of 14.4
months, range 7 months to 3 years), no variation in FEV1
values (mean FEV1 72.3%; range 43-91) or increase in
acute lung infections were found in our cohort of patients.
Discussion
The species of Sphingobacterium that were identified in this
study were S. multivorum (formerly Flavobacterium multivo-
rum, CDC group Ilk-2), and S. spiritovorum (includes spe-
cies formerly designated Flavobacterium spiritovorum,
Flavobacterium yabuuchiae, CDC group Ilk-3) [16].
Apart a previous anecdotic report in 1992 [12], this is the
first Italian report of the clinical and microbiological anal-
ysis of Sphingobacterium strains isolated from a cohort of
patients who are regularly attending a Regional CF Unit.
The existence of bacterial biodiversity in the CF lung is
well known [21] and, consequently, the correct identifica-
tion of different bacterial species is important. Given that
commercial systems for the phenotypic identification of
non-fermentative Gram-negative bacteria recovered from
CF patients appear to have some limitations, the isolation
of bacteria with selective media is crucial for the process-
ing of sputum samples from CF patients. In addition, the
CF community, the Centers for Disease Control and Pre-
vention and the American Society for Microbiology
endorse the use of selective media for processing respira-
tory tract specimens from CF patients [22]. The selective
medium used in this study was BCSA and the Sphingobac-
terium strains were able to grow on this medium. It is
interesting to note that BCSA contains gentamicin (0.01 g/
L), and the strains described were gentamicin resistant.
Nevertheless, Yabuuchi reported that some strains of
Sphingobacterium are susceptible to gentamicin [16].
In this study, we confirmed the phenotypic identification
of Sphingobacterium strains, using the Phoenix and API 20
NE systems, by other tests (DNase, oxidase, urease activity
and motility tests), as described by Yabuuchi [16].
Table 2: Percentage of Sphingobacterium strains resistant to the antibiotics tested.
AMK GEN ATM SXT FEP CTX CAZ MEM IPM CIP LVX PIP TZP CHL
S. spiritovorum (13) 100 100 100 0 100 100 0 0 0 0 0 0 0 100
S. multivorum (8) 100 100 100 0 100 100 100 100 62.5 0 0 100 100 100
AMK = Amikacin; GEN = Gentamicin; ATM = Aztreonam; SXT = Trimethoprim-sulfamethoxazole; FEP = Cefepim; CTX = Cefotaxim; CAZ = 
Ceftazidime; MEM = Meropenem; IPM = Imipenem; CIP = Ciprofloxacin; LVX = Levofloxacin; PIP = Piperacillin; TZP = Piperacillin/tazobactam; CHL 
= Chloramphenicol.
PFGE profiles of genomic DNA digested with ApaI of Sphingo- bacterium strains Figure 1
PFGE profiles of genomic DNA digested with ApaI of 
Sphingobacterium strains. From lanes 1 to 4: S. spiritovo-
rum strains from A to D profiles, respectively. From lanes 5 
to 7: S. multivorum strains from E to G profiles, respectively. 
Molecular size markers (a ladder of lambda phage DNA con-
catemers) were run in lanes St. Sizes are indicated in kilo-
bases.
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No data are available about antibiotic resistance and/or
susceptibility in Sphingobacteria in CF patients. In our
study the results of the antibiotic-susceptibility profile of
the strains showed that trimethoprim-sulfamethoxazole,
ciprofloxacin, and levofloxacin were effective against the
Sphingobacterium  strains, in agreement with previous
reports [9,23]. Considering that all patients are co-
infected by other bacteria, we suggest that antibiotic treat-
ment should be performed in pulmonary exacerbation.
We found that the strains showed a high degree of clonal
heterogeneity as demonstrated by PFGE, which yielded 7
different pulsed-types. It is noteworthy that these bacteria
are found in the natural environment and, therefore, stud-
ies on microbiological cultures and typing of Sphingobac-
terium from hospital environments are ongoing. On the
basis of our PFGE data, there is no evidence that Sphingo-
bacterium can spread from one patient to another in our
CF Center. However, a comprehensive epidemiological
survey is mandatory.
No subsequent decline in lung function was registered.
However, the follow-up period was too short to evaluate
the clinical impact of Sphingobacterium in CF patients. To
date, no further information is available about the role of
these bacteria during the progression of pulmonary dis-
ease in CF patients; neither, there is sufficient evidence to
define this microorganism as an emerging pathogen in CF
patients.
This pilot study suggests that correct identification, fol-
lowed by antibiotic-susceptibility testing and DNA-finger-
printing of all bacteria isolated from respiratory samples
of CF patients are necessary in order to monitor the poten-
tial impact of chronic lung infection on clinical outcome.
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